Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 9/2015

01.09.2015 | Review Article

The Economic and Humanistic Burden of Severe Sepsis

verfasst von: Bogdan Tiru, Ernest K. DiNino, Abigail Orenstein, Patrick T. Mailloux, Adam Pesaturo, Abhinav Gupta, William T. McGee

Erschienen in: PharmacoEconomics | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Sepsis and severe sepsis in particular remain a major health problem worldwide. Their cost to society extends well beyond lives lost, as the impact of survivorship is increasingly felt. A review of the medical literature was completed in MEDLINE using the search phrases “severe sepsis” and “septic shock” and the MeSH terms “epidemiology”, “statistics”, “mortality”, “economics”, and “quality of life”. Results were limited to human trials that were published in English from 2002 to 2014. Articles were classified by dominant themes to address epidemiology and outcomes, including quality of life of both patient and family caregivers, as well as societal costs. The severity of sepsis is determined by the number of organ failures and the presence of shock. In most developed countries, severe sepsis and septic shock account for disproportionate mortality and resource utilization. Although mortality rates have decreased, overall mortality continues to increase and is projected to accelerate as people live longer with more chronic illness. Among those who do survive, impaired quality of life, increased dependence, and rehospitalization increase healthcare consumption and, along with increased mortality, all contribute to the humanistic burden of severe sepsis. A large part of the economic burden of severe sepsis occurs after discharge. Initial inpatient costs represent only 30 % of the total cost and are related to severity and length of stay, whereas lost productivity and other indirect medical costs following hospitalization account for the majority of the economic burden of sepsis. Timeliness of treatment as well as avoidance of intensive care unit (ICU)-acquired illness/morbidity lead to important differences in both cost and outcome of treatment for severe sepsis and represent areas where improvement in care is possible. The degree of sophistication of a health system from a national perspective results in significant differences in resource use and outcomes for patients with serious infections. Comprehensive understanding of the cost and humanistic burden of severe sepsis provides an initial practical framework for health policy development and resource use.
Literatur
1.
Adhikari NKJ, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. The Lancet. 2010;376(9749):1339–46.CrossRef
2.
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.PubMedCrossRef
3.
Azoulay E, Alberti C, Legendre I, Buisson CB, Le Gall JR. Post-ICU mortality in critically ill infected patients: an international study. Intensive Care Med. 2005;31(1):56–63.PubMed
4.
Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41(5):1167–74.PubMedCrossRef
5.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10.PubMedCrossRef
6.
Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007;35(5):1244–50.PubMedCrossRef
7.
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Eng J Med. 2003;348(16):1546–54.CrossRef
8.
Wang HE, Shapiro NI, Angus DC, Yealy DM. National estimates of severe sepsis in United States emergency departments. Crit Care Med. 2007;35(8):1928–36.PubMedCrossRef
9.
Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med. 2012;40(3):754–61.PubMedCrossRef
10.
Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA. 2014;311(13):1308–16.PubMedCrossRef
11.
Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344–53.PubMedCrossRef
12.
Levy MM, Artigas A, Phillips GS, Rhodes A, Beale R, Osborn T, et al. Outcomes of the surviving sepsis campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis. 2012;12(12):919–24.PubMedCrossRef
13.
Reade MC, Yende S, D’Angelo G, Kong L, Kellum JA, Barnato AE, et al. Differences in immune response may explain lower survival among older men with pneumonia. Crit Care Med. 2009;37(5):1655–62.PubMedCentralPubMedCrossRef
14.
Yang Y, Yang KS, Hsann YM, Lim V, Ong BC. The effect of comorbidity and age on hospital mortality and length of stay in patients with sepsis. J Crit Care. 2010;25(3):398–405.PubMedCrossRef
15.
Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis*. Crit Care Med. 2006;34(1):15–21.PubMedCrossRef
16.
17.
Patel PR, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of bloodstream infections in hemodialysis patients. Am J Kidney Dis Off J Nat Kidney Found. 2010;56(3):566–77.CrossRef
18.
Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al. US Renal Data System 2012 Annual Data Report. Am J Kidney Dis Off J Nat Kidney Found. 2013;61(1 Suppl 1):A7, e1–476.
19.
Klevens RM, Edwards JR, Andrus ML, Peterson KD, Dudeck MA, Horan TC. Dialysis Surveillance Report: National Healthcare Safety Network (NHSN)-data summary for 2006. Semin Dial. 2008;21(1):24–8.PubMedCrossRef
20.
Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A. Critically ill cancer patient in intensive care unit: issues that arise. J Crit Care. 2014;29(5):817–22.PubMedCrossRef
21.
Frere P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E, et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2006;37(4):411–8.PubMedCrossRef
22.
Bock AM, Cao Q, Ferrieri P, Young JA, Weisdorf DJ. Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2013;19(1):102–8.CrossRef
23.
Arulkumaran N, West S, Chan K, Templeton M, Taube D, Brett SJ. Long-term renal function and survival of renal transplant recipients admitted to the intensive care unit. Clin Transplant. 2012;26(1):E24–31.PubMedCrossRef
24.
Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167(5):695–701.PubMedCrossRef
25.
Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis*. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2013;14(7):686–93.
26.
Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2005;6(3 Suppl):S3–5.
27.
Czaja AS, Zimmerman JJ, Nathens AB. Readmission and late mortality after pediatric severe sepsis. Pediatrics. 2009;123(3):849–57.PubMedCrossRef
28.
Wolfler A, Silvani P, Musicco M, Antonelli M, Salvo I. Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: a prospective national survey. Intensive Care Med. 2008;34(9):1690–7.PubMedCrossRef
29.
Skippen P, Kissoon N, Waller D, Northway T, Krahn G. Sepsis and septic shock: progress and future considerations. Indian J Pediatr. 2008;75(6):599–607.PubMedCrossRef
30.
Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? where? why? Lancet. 2005;365(9462):891–900.PubMedCrossRef
31.
Acosta CD, Knight M, Lee HC, Kurinczuk JJ, Gould JB, Lyndon A. The continuum of maternal sepsis severity: incidence and risk factors in a population-based cohort study. PloS One. 2013;8(7):e67175.PubMedCentralPubMedCrossRef
32.
Callaghan WM, Mackay AP, Berg CJ. Identification of severe maternal morbidity during delivery hospitalizations, United States, 1991–2003. Am J Obstet Gynecol. 2008;199(2):133 e1–8.
33.
34.
35.
Hsu B, editor. Healthcare costs, resource use, and mortality rates for sepsis in teaching versus non-teaching hospitals. 2013 AAP National Conference and Exhibition; 2013: American Academy of Pediatrics.
36.
37.
Walkey AJ, Wiener RS. Hospital case volume and outcomes among patients hospitalized with severe sepsis. Am J Respir Crit Care Med. 2014;189(5):548–55.PubMedCentralPubMedCrossRef
38.
Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med. 2003;29(9):1464–71.PubMedCrossRef
39.
Adrie C, Alberti C, Chaix-Couturier C, Azoulay E, De Lassence A, Cohen Y, et al. Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. J Crit Care. 2005;20(1):46–58.PubMedCrossRef
40.
Sznajder M, Leleu G, Buonamico G, Auvert B, Aegerter P, Merliere Y, et al. Estimation of direct cost and resource allocation in intensive care: correlation with Omega system. Intensive Care Med. 1998;24(6):582–9.PubMedCrossRef
41.
Moerer O, Plock E, Mgbor U, Schmid A, Schneider H, Wischnewsky MB, et al. A German national prevalence study on the cost of intensive care: an evaluation from 51 intensive care units. Crit Care. 2007;11(3):R69.PubMedCentralPubMedCrossRef
42.
Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004;8(5):R291–8.PubMedCentralPubMedCrossRef
43.
Braun L, Riedel AA, Cooper LM. Severe sepsis in managed care: analysis of incidence, one-year mortality, and associated costs of care. J Manag Care Pharm JMCP. 2004;10(6):521–30.PubMed
44.
Ernst FR, Malatestinic WN, Linde-Zwirble WT. Evaluating the clinical and financial impact of severe sepsis with Medicare or other administrative hospital data. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm. 2006;63(6):575–81.CrossRef
45.
Sogayar AM, Machado FR, Rea-Neto A, Dornas A, Grion CM, Lobo SM, et al. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics. 2008;26(5):425–34.PubMedCrossRef
46.
Schmid A, Pugin J, Chevrolet JC, Marsch S, Ludwig S, Stocker R, et al. Burden of illness imposed by severe sepsis in Switzerland. Swiss Med Wkly. 2004;134(7–8):97–102.PubMed
47.
Kaakeh R, Sweet BV, Reilly C, Bush C, DeLoach S, Higgins B, et al. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm. 2011;68(19):1811–9.
48.
Fox ER, Birt A, James KB, Kokko H, Salverson S, Soflin DL. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm. 2009;66(15):1399–406.CrossRef
49.
Blum RM, Stevens CA, Carter DM, Hussey AP, Marquis KA, Torbic H, et al. Implementation of a dexmedetomidine stewardship program at a tertiary academic medical center. Ann Pharmacother. 2013;47(11):1400–5.PubMedCrossRef
50.
Ho CK, Mabasa VH, Leung VW, Malyuk DL, Perrott JL. Assessment of clinical pharmacy interventions in the intensive care unit. Can J Hosp Pharm. 2013;66(4):212–8.PubMedCentralPubMed
51.
Aljbouri TM, Alkhawaldeh MS, Abu-Rumman AE, Hasan TA, Khattar HM, Abu-Oliem AS. Impact of clinical pharmacist on cost of drug therapy in the ICU. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2013;21(4):371–4.
52.
Saokaew S, Maphanta S, Thangsomboon P. Impact of pharmacist’s interventions on cost of drug therapy in intensive care unit. Pharm Pract. 2009;7(2):81–7.
53.
Jiang SP, Zhu ZY, Wu XL, Lu XY, Zhang XG, Wu BH. Effectiveness of pharmacist dosing adjustment for critically ill patients receiving continuous renal replacement therapy: a comparative study. Ther Clin Risk Manag. 2014;10:405–12.PubMedCentralPubMedCrossRef
54.
Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29(5):691–8.PubMed
55.
Zaidi ST, Hassan Y, Postma MJ, Ng SH. Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital. Pharm World Sci PWS. 2003;25(6):299–302.PubMedCrossRef
56.
Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm. 2007;64(23):2483–7.CrossRef
57.
Soguel L, Revelly JP, Schaller MD, Longchamp C, Berger MM. Energy deficit and length of hospital stay can be reduced by a two-step quality improvement of nutrition therapy: the intensive care unit dietitian can make the difference. Crit Care Med. 2012;40(2):412–9.PubMedCrossRef
58.
Merritt CL. Clinical imperative versus economic consequence: exploring the cost burden and opportunities in the care of patients with sepsis. Nurs Adm Q. 2011;35(1):61–7.PubMedCrossRef
59.
Nazer L, Al-Shaer M, Hawari F. Drug utilization pattern and cost for the treatment of severe sepsis and septic shock in critically ill cancer patients. Int J Clin Pharm. 2013;35(6):1245–50.PubMedCrossRef
60.
61.
Sanger-Katz M (2014 AHPSWFHCCISHTNYTRfhwn. The New York Times. 2014, 2 Aug 2014.
62.
63.
Wenzel RP, Edmond MB. Septic shock—evaluating another failed treatment. N Eng J Med. 2012;366(22):2122–4.CrossRef
64.
Poole D, Bertolini G, Garattini S. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis. 2009;9(1):67–72.PubMedCrossRef
65.
66.
Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012;7(Suppl 1):S57–67.PubMedCrossRef
67.
Rosner F. Allocation or misallocation of limited medical resources. Cancer Investig. 2004;22(5):810–2.CrossRef
68.
Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1225–36.PubMedCrossRef
69.
Schmid A, Burchardi H, Clouth J, Schneider H. Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ HEPAC Health Econ Prev Care. 2002;3(2):77–82.CrossRef
70.
Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med. 2003;31(9):2316–23.PubMedCrossRef
71.
Lee H, Doig CJ, Ghali WA, Donaldson C, Johnson D, Manns B. Detailed cost analysis of care for survivors of severe sepsis. Crit Care Med. 2004;32(4):981–5.PubMedCrossRef
72.
Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM. Population burden of long-term survivorship after severe sepsis in older Americans. J Am Geriatr Soc. 2012;60(6):1070–7.PubMedCentralPubMedCrossRef
73.
74.
Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med. 2010;38(5):1276–83.PubMed
75.
Quartin AA, Schein RM, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA. 1997;277(13):1058–63.PubMedCrossRef
76.
Yende S, D’Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177(11):1242–7.PubMedCentralPubMedCrossRef
77.
Myhren H, Ekeberg O, Stokland O. Health-related quality of life and return to work after critical illness in general intensive care unit patients: a 1-year follow-up study. Crit Care Med. 2010;38(7):1554–61.PubMedCrossRef
78.
Oeyen SG, Vandijck DM, Benoit DD, Annemans L, Decruyenaere JM. Quality of life after intensive care: a systematic review of the literature. Crit Care Med. 2010;38(12):2386–400.PubMedCrossRef
79.
Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787–94.PubMedCentralPubMedCrossRef
80.
Shah FA, Pike F, Alvarez K, Angus D, Newman AB, Lopez O, et al. Bidirectional relationship between cognitive function and pneumonia. Am J Respir Crit Care Med. 2013;188(5):586–92.PubMedCentralPubMedCrossRef
81.
Granja C, Dias C, Costa-Pereira A, Sarmento A. Quality of life of survivors from severe sepsis and septic shock may be similar to that of others who survive critical illness. Crit Care. 2004;8(2):R91–8.PubMedCentralPubMedCrossRef
82.
Hofhuis JG, Spronk PE, van Stel HF, Schrijvers AJ, Rommes JH, Bakker J. The impact of severe sepsis on health-related quality of life: a long-term follow-up study. Anesth Analg. 2008;107(6):1957–64.PubMedCrossRef
83.
Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettila V. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med. 2009;37(4):1268–74.PubMedCrossRef
84.
Davydow DS, Hough CL, Langa KM, Iwashyna TJ. Symptoms of depression in survivors of severe sepsis: a prospective cohort study of older Americans. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2013;21(9):887–97.CrossRef
85.
Angus DC. The lingering consequences of sepsis: a hidden public health disaster? JAMA. 2010;304(16):1833–4.PubMedCrossRef
86.
Adelman RD, Tmanova LL, Delgado D, Dion S, Lachs MS. Caregiver burden: a clinical review. JAMA. 2014;311(10):1052–60.PubMedCrossRef
87.
Van Pelt DC, Schulz R, Chelluri L, Pinsky MR. Patient-specific, time-varying predictors of post-ICU informal caregiver burden: the caregiver outcomes after ICU discharge project. Chest. 2010;137(1):88–94.PubMedCentralPubMedCrossRef
88.
Van Pelt DC, Milbrandt EB, Qin L, Weissfeld LA, Rotondi AJ, Schulz R, et al. Informal caregiver burden among survivors of prolonged mechanical ventilation. Am J Respir Crit Care Med. 2007;175(2):167–73.PubMedCentralPubMedCrossRef
89.
Paratz JD, Kenardy J, Mitchell G, Comans T, Coyer F, Thomas P, et al. IMPOSE (IMProving Outcomes after Sepsis)—the effect of a multidisciplinary follow-up service on health-related quality of life in patients postsepsis syndromes—a double-blinded randomised controlled trial: protocol. BMJ Open. 2014;4(5):e004966.PubMedCentralPubMedCrossRef
90.
Zampieri FG, Colombari F. The impact of performance status and comorbidities on the short-term prognosis of very elderly patients admitted to the ICU. BMC Anesthesiol. 2014;14:59.PubMedCentralPubMedCrossRef
91.
Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al. Comparison of two fluid-management strategies in acute lung injury. N Eng J Med. 2006;354(24):2564–75.CrossRef
92.
Raghunathan K, McGee WT, Higgins T. Importance of intravenous fluid dose and composition in surgical ICU patients. Curr Opin Crit Care. 2012;18(4):350–7.PubMedCrossRef
93.
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Eng J Med. 2000;342(18):1301–8.
94.
Sevick MA, Bradham DD. Economic value of caregiver effort in maintaining long-term ventilator-assisted individuals at home. Heart Lung J Crit Care. 1997;26(2):148–57.CrossRef
95.
Hanly P, Ceilleachair AO, Skally M, O’Leary E, Kapur K, Fitzpatrick P, et al. How much does it cost to care for survivors of colorectal cancer? Caregiver’s time, travel and out-of-pocket costs. Support Care Cancer Off J Multinat Assoc Support Care Cancer. 2013;21(9):2583–92.CrossRef
96.
van den Berg B, Al M, van Exel J, Koopmanschap M, Brouwer W. Economic valuation of informal care: conjoint analysis applied in a heterogeneous population of informal caregivers. Value Health J Int Soc Pharmacoecon Outcomes Res. 2008;11(7):1041–50.CrossRef
97.
Prescott HC, Langa KM, Liu V, Escobar GJ, Iwashyna TJ. Increased 1-year healthcare use in survivors of severe sepsis. Am J Respir Crit Care Med. 2014;190(1):62–9.PubMedCentralPubMedCrossRef
Metadaten
Titel
The Economic and Humanistic Burden of Severe Sepsis
verfasst von
Bogdan Tiru
Ernest K. DiNino
Abigail Orenstein
Patrick T. Mailloux
Adam Pesaturo
Abhinav Gupta
William T. McGee
Publikationsdatum
01.09.2015
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 9/2015
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-015-0282-y

Weitere Artikel der Ausgabe 9/2015

PharmacoEconomics 9/2015 Zur Ausgabe

Letter to the Editor

The Authors’ Reply: Comment on “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”

Review Article

Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective

Letter to the Editor

Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”

Original Research Article

A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark

Review Article

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review

Practical Application

Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic Evaluation